Page last updated: 2024-12-05

5,5'-dimethyl-2,2'-bipyridyl

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5,5'-dimethyl-2,2'-bipyridyl is a bidentate ligand commonly used in coordination chemistry. It is a derivative of 2,2'-bipyridine, with two methyl groups added at the 5 and 5' positions. These methyl groups enhance the electron-donating ability of the ligand, which can influence the properties of metal complexes formed with it. The synthesis of 5,5'-dimethyl-2,2'-bipyridyl typically involves a reaction between 2,5-dimethylpyridine and a suitable oxidizing agent, such as potassium permanganate. Its importance lies in its ability to form stable and luminescent complexes with various transition metals, particularly ruthenium, which find applications in areas like photocatalysis, organic light-emitting diodes (OLEDs), and solar energy conversion. 5,5'-dimethyl-2,2'-bipyridyl and its metal complexes are studied for their potential in diverse applications due to their unique electronic and optical properties. The methyl groups on the ligand can influence the energy levels of the metal complexes and contribute to their photophysical properties, such as emission wavelength and quantum yield. The compound is also explored for its use in sensing applications due to its sensitivity to changes in its environment. '

5,5'-dimethyl-2,2'-bipyridyl: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID15664
CHEMBL ID2205807
CHEBI ID192617
SCHEMBL ID351152
MeSH IDM0516063

Synonyms (55)

Synonym
brn 0123183
5,5'-dimethyl-2,2'-bipyridine
2,2'-bipyridine, 5,5'-dimethyl-
5,5'-dimethyl-2,2'-dipyridyl, 98%
6,6'-di-3-picoline
6,6'-bi-3-picoline
5,5'-dimethyl-2,2'-bipyridyl
B2138
1762-34-1
5,5'-dimethyl-2,2'-dipyridyl
6,6'-di-3-picolyl
abametapir
5-methyl-2-(5-methylpyridin-2-yl)pyridine
CHEBI:192617
AKOS005257775
unii-6uo390amfb
xeglyze
6uo390amfb ,
abametapir [usan:inn]
ha-44
CHEMBL2205807 ,
bdbm50401351
ha44
FT-0689891
S5752
SCHEMBL351152
abametapir [mi]
abametapir [inn]
abametapir [who-dd]
abametapir [usan]
abametapir [orange book]
xeglyze (tn)
abametapir (usan/inn)
D10687
W-108621
2,2 -bis-(5-methylpyridyl)
PTRATZCAGVBFIQ-UHFFFAOYSA-N
DTXSID00170095
mfcd01740554
D70523
CS-W004546
xeglyze(abametapir)
DB11932
SY052805
5,5 inverted exclamation mark -dimethyl-2,2 inverted exclamation mark -bipyridyl
LT0042
DS-15219
SB17220
Q27265547
5,5'-dimethyl-2,2'-bipyridinyl
YSSJ3184
HY-W004546
EN300-263878
abametapirum
Z1255488813
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
bipyridinesCompounds containing a bipyridine group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
C-C chemokine receptor type 1Homo sapiens (human)IC50 (µMol)201.76300.00070.20022.5000AID716289
C-C chemokine receptor type 5Homo sapiens (human)IC50 (µMol)202.76300.00020.25679.0000AID716287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
C-C chemokine receptor type 1Homo sapiens (human)EC50 (µMol)16.42441.50002.98566.3096AID716296
C-C chemokine receptor type 5Homo sapiens (human)EC50 (µMol)2.40590.00702.09365.0119AID716295
C-C chemokine receptor type 8Homo sapiens (human)EC50 (µMol)7.72160.48003.72297.9433AID716294
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (34)

Processvia Protein(s)Taxonomy
dendritic cell chemotaxisC-C chemokine receptor type 1Homo sapiens (human)
monocyte chemotaxisC-C chemokine receptor type 1Homo sapiens (human)
calcium ion transportC-C chemokine receptor type 1Homo sapiens (human)
intracellular calcium ion homeostasisC-C chemokine receptor type 1Homo sapiens (human)
exocytosisC-C chemokine receptor type 1Homo sapiens (human)
chemotaxisC-C chemokine receptor type 1Homo sapiens (human)
immune responseC-C chemokine receptor type 1Homo sapiens (human)
cell adhesionC-C chemokine receptor type 1Homo sapiens (human)
cell surface receptor signaling pathwayC-C chemokine receptor type 1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerC-C chemokine receptor type 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-C chemokine receptor type 1Homo sapiens (human)
cell-cell signalingC-C chemokine receptor type 1Homo sapiens (human)
response to woundingC-C chemokine receptor type 1Homo sapiens (human)
negative regulation of gene expressionC-C chemokine receptor type 1Homo sapiens (human)
cytokine-mediated signaling pathwayC-C chemokine receptor type 1Homo sapiens (human)
positive regulation of cell migrationC-C chemokine receptor type 1Homo sapiens (human)
negative regulation of bone mineralizationC-C chemokine receptor type 1Homo sapiens (human)
positive regulation of osteoclast differentiationC-C chemokine receptor type 1Homo sapiens (human)
positive regulation of calcium ion transportC-C chemokine receptor type 1Homo sapiens (human)
chemokine-mediated signaling pathwayC-C chemokine receptor type 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeC-C chemokine receptor type 1Homo sapiens (human)
positive regulation of monocyte chemotaxisC-C chemokine receptor type 1Homo sapiens (human)
calcium-mediated signalingC-C chemokine receptor type 1Homo sapiens (human)
cell chemotaxisC-C chemokine receptor type 1Homo sapiens (human)
inflammatory responseC-C chemokine receptor type 1Homo sapiens (human)
MAPK cascadeC-C chemokine receptor type 5Homo sapiens (human)
dendritic cell chemotaxisC-C chemokine receptor type 5Homo sapiens (human)
calcium ion transportC-C chemokine receptor type 5Homo sapiens (human)
chemotaxisC-C chemokine receptor type 5Homo sapiens (human)
cellular defense responseC-C chemokine receptor type 5Homo sapiens (human)
cell surface receptor signaling pathwayC-C chemokine receptor type 5Homo sapiens (human)
G protein-coupled receptor signaling pathwayC-C chemokine receptor type 5Homo sapiens (human)
cell-cell signalingC-C chemokine receptor type 5Homo sapiens (human)
release of sequestered calcium ion into cytosol by sarcoplasmic reticulumC-C chemokine receptor type 5Homo sapiens (human)
calcium-mediated signalingC-C chemokine receptor type 5Homo sapiens (human)
signalingC-C chemokine receptor type 5Homo sapiens (human)
symbiont entry into host cellC-C chemokine receptor type 5Homo sapiens (human)
chemokine-mediated signaling pathwayC-C chemokine receptor type 5Homo sapiens (human)
response to cholesterolC-C chemokine receptor type 5Homo sapiens (human)
cellular response to lipopolysaccharideC-C chemokine receptor type 5Homo sapiens (human)
negative regulation of macrophage apoptotic processC-C chemokine receptor type 5Homo sapiens (human)
inflammatory responseC-C chemokine receptor type 5Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-C chemokine receptor type 5Homo sapiens (human)
immune responseC-C chemokine receptor type 5Homo sapiens (human)
cell chemotaxisC-C chemokine receptor type 5Homo sapiens (human)
chemotaxisC-C chemokine receptor type 8Homo sapiens (human)
cell adhesionC-C chemokine receptor type 8Homo sapiens (human)
G protein-coupled receptor signaling pathwayC-C chemokine receptor type 8Homo sapiens (human)
chemokine-mediated signaling pathwayC-C chemokine receptor type 8Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-C chemokine receptor type 8Homo sapiens (human)
immune responseC-C chemokine receptor type 8Homo sapiens (human)
cell chemotaxisC-C chemokine receptor type 8Homo sapiens (human)
calcium-mediated signalingC-C chemokine receptor type 8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (11)

Processvia Protein(s)Taxonomy
phosphatidylinositol phospholipase C activityC-C chemokine receptor type 1Homo sapiens (human)
chemokine receptor activityC-C chemokine receptor type 1Homo sapiens (human)
protein bindingC-C chemokine receptor type 1Homo sapiens (human)
C-C chemokine receptor activityC-C chemokine receptor type 1Homo sapiens (human)
C-C chemokine bindingC-C chemokine receptor type 1Homo sapiens (human)
chemokine (C-C motif) ligand 7 bindingC-C chemokine receptor type 1Homo sapiens (human)
chemokine (C-C motif) ligand 5 bindingC-C chemokine receptor type 1Homo sapiens (human)
virus receptor activityC-C chemokine receptor type 5Homo sapiens (human)
actin bindingC-C chemokine receptor type 5Homo sapiens (human)
phosphatidylinositol phospholipase C activityC-C chemokine receptor type 5Homo sapiens (human)
chemokine receptor activityC-C chemokine receptor type 5Homo sapiens (human)
protein bindingC-C chemokine receptor type 5Homo sapiens (human)
coreceptor activityC-C chemokine receptor type 5Homo sapiens (human)
C-C chemokine receptor activityC-C chemokine receptor type 5Homo sapiens (human)
C-C chemokine bindingC-C chemokine receptor type 5Homo sapiens (human)
identical protein bindingC-C chemokine receptor type 5Homo sapiens (human)
chemokine (C-C motif) ligand 5 bindingC-C chemokine receptor type 5Homo sapiens (human)
chemokine receptor activityC-C chemokine receptor type 8Homo sapiens (human)
coreceptor activityC-C chemokine receptor type 8Homo sapiens (human)
C-C chemokine receptor activityC-C chemokine receptor type 8Homo sapiens (human)
C-C chemokine bindingC-C chemokine receptor type 8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
plasma membraneC-C chemokine receptor type 1Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 1Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 1Homo sapiens (human)
cytoplasmC-C chemokine receptor type 1Homo sapiens (human)
cell surfaceC-C chemokine receptor type 5Homo sapiens (human)
endosomeC-C chemokine receptor type 5Homo sapiens (human)
plasma membraneC-C chemokine receptor type 5Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 5Homo sapiens (human)
cell surfaceC-C chemokine receptor type 5Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 5Homo sapiens (human)
cytoplasmC-C chemokine receptor type 5Homo sapiens (human)
plasma membraneC-C chemokine receptor type 8Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID716297Allosteric modulation at human CCR1 transfected in COS7 cells coexpressing chimeric Gqi4myr assessed as [3H]IP3 turnover by liquid scintillation counting analysis relative to basal level2012Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18
Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors.
AID716288Displacement of [125I]-CCL3 from human CCR1 transfected in COS7 cells coexpressing chimeric Gqi4myr after 3 hrs relative to basal level2012Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18
Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors.
AID716294Allosteric modulation at human CCR8 transfected in COS7 cells assessed as [3H]IP3 turnover by liquid scintillation counting analysis2012Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18
Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors.
AID716296Allosteric modulation at human CCR1 transfected in COS7 cells coexpressing chimeric Gqi4myr assessed as {3H]IP3 turnover by liquid scintillation counting analysis2012Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18
Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors.
AID716293Binding affinity to Zn(II) after 2 hrs using FluoZin-3 by fuorescence assay2012Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18
Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors.
AID716295Allosteric modulation at human CCR5 transfected in COS7 cells coexpressing chimeric Gqi4myr assessed as [3H]IP3 turnover by liquid scintillation counting analysis2012Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18
Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors.
AID716289Displacement of [125I]-CCL3 from human CCR1 transfected in COS7 cells coexpressing chimeric Gqi4myr after 3 hrs2012Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18
Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors.
AID716298Allosteric modulation at human CCR5 transfected in COS7 cells coexpressing chimeric Gqi4myr assessed as [3H]IP3 turnover by liquid scintillation counting analysis relative to basal level2012Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18
Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors.
AID716287Displacement of [125I]-CCL3 from human CCR5 transfected in COS7 cells coexpressing chimeric Gqi4myr after 3 hrs2012Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18
Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors.
AID716299Ratio of ZnBip EC50 to compound EC50 for human CCR1 transfected in COS7 cells coexpressing chimeric Gqi4myr assessed as IP3 turnover by liquid scintillation counting analysis2012Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18
Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors.
AID716286Displacement of [125I]-CCL3 from human CCR5 transfected in COS7 cells coexpressing chimeric Gqi4myr after 3 hrs relative to basal level2012Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18
Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors.
AID716292Ratio of ZnBip EC50 to compound EC50 for human CCR8 transfected in COS7 cells coexpressing chimeric Gqi4myr assessed as IP3 turnover by liquid scintillation counting analysis2012Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18
Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors.
AID716301Ratio of ZnBip EC50 to compound EC50 for human CCR5 transfected in COS7 cells coexpressing chimeric Gqi4myr assessed as IP3 turnover by liquid scintillation counting analysis2012Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18
Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors.
AID716290Allosteric modulation at human CCR8 transfected in COS7 cells coexpressing chimeric Gqi4myr assessed as [3H]IP3 turnover by liquid scintillation counting analysis relative to basal level2012Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18
Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (25.00)29.6817
2010's3 (37.50)24.3611
2020's3 (37.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.18 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.88 (4.65)
Search Engine Demand Index32.99 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]